Diskusjon Triggere Porteføljer Aksjonærlister

Navamedic (NAVA)

Biotek
#385

Record-high revenues for 4Q

Navamedic announced its 4Q results this morning. Reported revenues came in as expected at NOK 116m, but lower than foreseen operational costs and COGS led to a 22% better result on the EBITDA. The company has once again over-delivered on its guided goals. We remain positive about Navamedic’s outlook and will raise our estimates and TP.

Revenues as expected and strong EBITDA

Quarterly revenues came in very close to our estimate, at an all-time high of NOK 116m, 29% higher than 4Q21. For the full year of 2022, revenues amounted to NOK 382.1m (YoY growth rate of 37%). All product categories had reported revenues without large deviations from our expectations and were led by the Specialty Pharma (Mysimba) category with FY22 revenue of NOK 159m (NOK 112m FY21). The gross margin of 42.9% was once again above the guided 40%. EBITDA of NOK 15.7m was higher than our estimate of NOK 12.9m, which led to a 13.5% EBITDA margin. Net earnings of NOK 20.2 also outperformed our estimates. However, it was impacted by positive net financial items of NOK 13.2m, mostly due to the reversal of license liabilities for products no longer marketed. (Norne Research)

2 Likes
#386

At Reiten & Co kom inn i NAVA har vært positivt.
De er største eier i OBSRV og vil nok sørge for suksess også der.

3 Likes
#387

NAVAMEDIC ASA: GRANT OF OPTIONS TO PRIMARY INSIDERS

1 Like
#388

De blir millionærer hele bunten :grinning:

#389

Vi få håpe Navamedic ikke binder seg mer opp til Observer, de har utestående lån på 40mil og aksjer i Observer.

#390

Norne øker kursmålet:

TP increased to NOK 55/sh, Buy reiterated

Navamedic has ambitious growth and profitability improvement plans, which so far have exceeded promises and our estimates consistently. We believe that the company still has plenty of opportunities to grow its top and bottom line. After increasing our estimates, we arrive at a new Target Price of NOK 55/sh (48) and maintain our Buy recommendation. While it’s hard to find good public peers to Navamedic, a broad relevant company comparison also reaffirms our bullish DCF valuation.

#391

Flagging notification Navamedic ASA

#392

Navamedic ASA: Recommended cash offer to acquire Sensidose for approximately SEK 75 million

#393

Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB

#394

Navamedic ASA: Annual Report for 2022

#395

Navamedic ASA: Invitation to 2023 1st quarter presentation

#396

Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag

1 Like
#397

Navamedic ASA Q1 2023: Nok et sterkt kvartal

2 Likes
#398

Navamedic ASA Q1 2023: Another strong quarter

1 Like
#399

““We have had a strong start to 2023, and we are now well on our way to becoming
a NOK 1 billion company. Our growth is driven by the successful build-up of our
diversified product categories, and we have experienced continued demand for
products across our business areas,” commented Kathrine Gamborg Andreassen, CEO
of Navamedic.”

122 mill. i omsetning og EBITDA på 14 mill.
Tenk om vi hadde hatt slike rapporter fra Photocure. (likevel er Photocure verdt mer enn det dobbelte av Navamedic.)

2 Likes
#400

Navamedic ASA: Notice of Annual General Meeting

#401

Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer

#402

Updated recommendation by the nomination committee of Navamedic ASA

#403

Navamedic ASA: Minutes of Annual General Meeting

#404

"Sensidose deal closed, but a lot of work awaits

Navamedic closed the Sensidose saga as the last remaining shares will be bought out in the following days. The acquisition is logical and fair, but the risk of Navamedic increases due to Sensidose’s lack of commercialization, therefore we keep the Target Price of NOK 53/sh unchanged and maintain Buy recommendation.

1Q Revenues and EBITDA above estimates

In the 1Q report last month Navamedic delivered another record-high quarterly revenue of NOK 122m. We were expecting a slight decrease from the seasonally strongest 4Q, thus figures have beaten our estimates by 9%. EBITDA margin came in at 13.0%, a tad lower than our expected 13.6%. The net result has been affected by net currency gains of NOK 8m, leading to an overperformance on the bottom line. This gain largely reverses last year’s currency losses of NOK 9.2m. Additionally, Navamedic acquired the rights to distribute and sell Alflorex®, an over-the-counter product for irritable bowel syndrome (IBS), in Sweden." (Norne Sec.)